Oramed Reports Fiscal Third Quarter 2025 Financial Results
Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK , Nov. 17, 2025 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
NEW YORK , Nov. 17, 2025 /PRNewswire/ — The Board of Directors of Oramed Pharmaceuticals Inc. (the “Company”) announced today that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the “Rights Plan”), by and between the Company and Continental Stock Transfer & Trust Company ,
